500-64-1
Chemical Structure
(+)-Kavain
- CAS No.: 500-64-1
- Formula:C14H14O3
- Molecular Weight:230.26
IUPAC Name: (R,E)-4-methoxy-6-styryl-5,6-dihydro-2H-pyran-2-one
InChIKey: XEAQIWGXBXCYFX-GUOLPTJISA-N
SMILES: O=C1C=C(OC)C[C@H](/C=C/C2=CC=CC=C2)O1
Biological Activity: (+)-Kavain, a main kavalactone that can be extracted from Piper methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na+ and Ca2+ channels[1]. (+)-Kavain is shown to bind at the α4β2δ GABAA receptor and potentiate GABA efficacy[2]. (+)-Kavain is used as a treatment for inflammatory diseases, its anti-inflammatory action has been widely studied[4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(+)-Kavain | 99.10% | (+)-Kavain, a main kavalactone that can be extracted from Piper methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na+ and Ca2+ channels. (+)-Kavain is shown to bind at the α4β2δ GABAA receptor and potentiate GABA efficacy. (+)-Kavain is used as a treatment for inflammatory diseases, its anti-inflammatory action has been widely studied. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(+)-Kavain (Standard) | ≥98% | (+)-Kavain (Standard) is the analytical standard of (+)-Kavain. This product is intended for research and analytical applications. (+)-Kavain, a main kavalactone extracted from Piper methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na+ and Ca2+ channels. (+)-Kavain is shown to bind at the α4β2δ GABAA receptor and potentiate GABA efficacy. (+)-Kavain is used as a treatment for inflammatory diseases, its anti-inflammatory action has been widely studied. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Bradić I, et al. [Hirschsprung's disease -- therapy and results]. Acta Chir Iugosl. 1975;22(2):183-95. [Content Brief]
- [2]. Chua HC, et al. Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism. PLoS One. 2016 Jun 22;11(6):e0157700. [Content Brief]
- [4]. Tang X, et al. Kavain Inhibition of LPS-Induced TNF-α via ERK/LITAF. Toxicol Res (Camb). 2016 Jan 1;5(1):188-196. [Content Brief]
Keywords
